Vanda Pharmaceuticals Inc.
NASDAQ:VNDA · NASDAQ Global Market
-$0.20 today
Vol 1.57M · Avg 1.29M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:VNDA · Revenue to Net Income
Key Ratios
Analysis
$217.8M of revenue converted into -$239.5M of net income for the selected period. Gross margin is 92.4% and net margin is -108.1%, showing how much revenue survives after costs and taxes. EPS is $-4.05, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $216.1M +8.7% | $198.8M +3.2% | $192.6M -24.3% | $254.4M -5.3% | $268.7M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $13.0M +15.3% | $11.3M -23.5% | $14.8M -39.1% | $24.3M -5.3% | $25.6M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $203.1M +8.3% | $187.5M +5.4% | $177.8M -22.7% | $230.1M -5.3% | $243.1M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 94.0% -0.3pp | 94.3% +2.0pp | 92.3% +1.9pp | 90.5% -0.0pp | 90.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $109.3M +46.8% | $74.4M -3.1% | $76.8M -10.4% | $85.8M +13.8% | $75.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $238.0M +62.5% | $146.4M +29.7% | $112.9M -17.3% | $136.5M +10.0% | $124.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $354.2M +55.3% | $228.1M +18.9% | $191.8M -14.3% | $223.8M +11.4% | $200.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $11.9M +46.5% | $8.1M +170.2% | $3.0M +10.1% | $2.7M -3.8% | $2.8M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$126.7M -756.9% | -$14.8M -258.2% | $9.3M -33.4% | $14.0M -69.0% | $45.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -58.6% -51.2pp | -7.4% -12.3pp | 4.9% -0.7pp | 5.5% -11.3pp | 16.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$151.2M -271.8% | -$40.7M -191.4% | -$14.0M -320.4% | $6.3M -85.0% | $42.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -70.0% -49.5pp | -20.5% -13.2pp | -7.2% -9.7pp | 2.5% -13.2pp | 15.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 -100.0% | $199.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $12.5M -29.4% | $17.7M -12.6% | $20.3M +308.2% | $5.0M +2398.0% | $199.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$138.6M -504.9% | -$22.9M -461.6% | $6.3M -43.9% | $11.3M -73.3% | $42.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -64.2% -52.6pp | -11.5% -14.8pp | 3.3% -1.2pp | 4.4% -11.3pp | 15.8% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $81.8M +2135.0% | -$4.0M -205.0% | $3.8M -23.8% | $5.0M -45.5% | $9.2M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$220.5M -1066.5% | -$18.9M -853.3% | $2.5M -60.0% | $6.3M -81.1% | $33.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | -102.0% -92.5pp | -9.5% -10.8pp | 1.3% -1.2pp | 2.5% -9.9pp | 12.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$4 -1068.8% | -$0 -832.3% | $0 -60.3% | $0 -81.7% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$4 -1068.8% | -$0 -833.9% | $0 -60.4% | $0 -81.0% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $58.9M +1.3% | $58.1M +1.3% | $57.4M +1.6% | $56.5M +1.6% | $55.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $58.9M +1.3% | $58.1M +1.0% | $57.6M +1.0% | $57.0M +0.1% | $56.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.29B
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$504.57M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$484.08M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$343.72M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$265.53M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$222.97M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$217.16M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$211.33M
Immuneering Corporation
NASDAQ:IMRX
$156.43M
Humacyte, Inc.
NASDAQ:HUMA
$152.88M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does VNDA generate?
Vanda Pharmaceuticals Inc. (VNDA) reported $216.10M of revenue in fiscal 2025.
Is VNDA profitable?
Vanda Pharmaceuticals Inc. (VNDA) reported -$220,474,000.00 of net income, with a net margin of -102.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.